Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Prospective Phase III Comparison of Paclitaxel-Carboplatin Versus Docetaxel-Carboplatin as First Line Chemotherapy in Stage Ic-IV Epithelial Ovarian Cancer

NCT00003998 is registered in ClinicalTrials.gov with University of Glasgow as lead sponsor.

NCT NCT00003998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Prospective Phase III Comparison of Paclitaxel-Carboplatin Versus Docetaxel-Carboplatin as First Line Chemotherapy in Stage Ic-IV Epithelial Ovarian Cancer
Lead sponsor
University of Glasgow
Phase
Phase 3
Overall status
Completed
Start date
October 31, 1998
Completion date
December 31, 2004
Enrollment
1,050 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, primary peritoneal cavity cancer